Pulmonary diseases are one of the most important causes of morbidity and mortality. Although vitamin D is best known for its role in calcium, phosphorus, and bone homeostasis, it has gained attention in the recent years because of a wide range of extraskeletal effects, including its immunomodulatory and antibacterial potential. Vitamin D deficiency is highly prevalent in chronic pulmonary diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, tuberculosis, and asthma, and several clinical studies have been conducted investigating the effect of vitamin D supplementation on disease outcomes. In this review, we searched for positive evidence on vitamin D supplementation from randomized controlled trials and elaborated on the optimal serum vitamin D levels and dosing regimens for an effective intervention. While vitamin D supplementation seems to be beneficial as an add -on treatment for adult patients with asthma and a potent intervention to reduce exacerbations in patients with COPD, there is little evidence for its therapeutic use in cystic fibrosis, pneumonia, and tuberculosis. the debate on the appropriate levels of 25(OH)D is still ongoing, most studies define the levels of less than 20 ng/ml (50 nmol/l) as deficient because they are associated with chronic diseases. 5 This is also the threshold used in most governmental guidelines for vitamin D. 16 The levels below 10 ng/ml (25 nmol/l) are considered as severe deficiency because they are associated with an increased risk of rickets or osteomalacia. It is also assumed that patients with these levels exhibit a true risk for infections and chronic diseases. 17 Other research groups reported that the serum 25(OH)D concentrations of 30 ng/ml (75 nmol/l) or even higher, as found in native populations living around the equator, are needed for optimal health. 5,10 Importance of vitamin D in pulmonary diseases Vitamin D deficiency is associated with multiple diseases such as cancer, hypertension, and autoimmune diseases, but also with several lung diseases. 5 A recent meta -analysis demonstrated that vitamin D levels are significantly lower in patients with tuberculosis (TB) compared with controls (apart from the African population). 18 About 70% to 90% of patients with TB have 25(OH)D levels below 20 ng/ml. 19, 20 Janssens et al 6 demonstrated that patients with COPD had significantly lower 25(OH)D levels compared with healthy smokers and that vitamin D deficiency correlated with disease severity. While 31% of the healthy smokers were vitamin D deficient, this percentage increased gradually to 60% in stage 3 of COPD according to the Global Initiative for Obstructive Lung Disease (GOLD) to even 77% in the most severe stage of the disease.
renin synthesis and an increased skeletal muscle strength, but also numerous immunomodulatory effects controlling immune activation on one side and enhancing anti -infectious defense on the other. 2 Vitamin D deficiency is highly prevalent in the overall population. In Europe, 42% of all adults are considered to be vitamin D deficient, with 25(OH)D levels below 20 ng/ml.
4 Vitamin D deficiency is even more present in patients with pulmonary diseases such as COPD, asthma, and CF. [5] [6] [7] Given the possible immunomodulatory effects of vitamin D and the important fraction of patients with severe vitamin D deficiency in these diseases, multiple studies have tested the effect of vitamin D supplementation on clinical outcomes. In this review, we will discuss most of the randomized placebo -controlled vitamin D intervention studies to determine which patients with pulmonary diseases may benefit from vitamin D supplementation.
Vitamin D pathway Most vitamin D is produced in the skin by conversion of 7 -dehydrocholesterol
Introduction Pulmonary diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis (CF) are an important cause of morbidity and mortality. As these diseases cannot be cured, current therapeutic strategies focus on symptom control and aim to limit disease progression by blocking inflammation and preventing infections. Although different strategies have been developed that reduce inflammation and improve bacterial and viral clearance, there is still a need for new effective therapies.
Vitamin D is most known for its role in bone homeostasis by regulating calcium and phosphorus metabolism.
1 Over the last decades, it has become apparent that vitamin D also exerts noncalcemic effects. The vitamin D receptor (VDR) and vitamin D -regulating enzymes are expressed in multiple cell types, including cells that are not involved in bone homeostasis. Approximately 3% of the human genome (more than 200 genes) is regulated by vitamin D.
1-3 Many of those genes are involved in noncalcemic pathways. These so called noncalcemic effects of vitamin D include an increase in insulin production, a decreased the debate on the appropriate levels of 25(OH)D is still ongoing, most studies define the levels of less than 20 ng/ml (50 nmol/l) as deficient because they are associated with chronic diseases. 5 This is also the threshold used in most governmental guidelines for vitamin D. 16 The levels below 10 ng/ml (25 nmol/l) are considered as severe deficiency because they are associated with an increased risk of rickets or osteomalacia. It is also assumed that patients with these levels exhibit a true risk for infections and chronic diseases. 17 Other research groups reported that the serum 25(OH)D concentrations of 30 ng/ml (75 nmol/l) or even higher, as found in native populations living around the equator, are needed for optimal health. 5, 10 Importance of vitamin D in pulmonary diseases Vitamin D deficiency is associated with multiple diseases such as cancer, hypertension, and autoimmune diseases, but also with several lung diseases. 5 A recent meta -analysis demonstrated that vitamin D levels are significantly lower in patients with tuberculosis (TB) compared with controls (apart from the African population). 18 About 70% to 90% of patients with TB have 25(OH)D levels below 20 ng/ml. 19, 20 Janssens et al 6 demonstrated that patients with COPD had significantly lower 25(OH)D levels compared with healthy smokers and that vitamin D deficiency correlated with disease severity. While 31% of the healthy smokers were vitamin D deficient, this percentage increased gradually to 60% in stage 3 of COPD according to the Global Initiative for Obstructive Lung Disease (GOLD) to even 77% in the most severe stage of the disease.
Vitamin D deficiency is also highly prevalent in CF. Up to 75% of adults and 95% of pediatric patients with CF are vitamin D deficient, [21] [22] [23] despite routine oral supplementation. 24 In patients with CF, vitamin D deficiency seems to be associated with a decreased pulmonary function in adults, 25,26 but not in children. 24,27 Moreover, Bener et al 28 revealed that vitamin D deficiency was more common in asthmatic children (52.9%) compared with healthy children (35.5%). Also in interstitial lung diseases, there is a high prevalence of vitamin D deficiency, with clear correlations between 25(OH)D levels and a reduced lung function. 29 It is not clear whether vitamin D deficiency is more common in patients with pneumonia compared with controls. Although Muhe et al 30 identified a higher incidence of vitamin D deficiency in children with pneumonia compared with controls, other studies did not confirm these results.
31,32
There are multiple reasons for the high prevalence of vitamin D deficiency in patients with chronic lung diseases. The most likely explanation is that people who are severely ill and have a limited exercise capacity spend less time outdoor and have less sun exposure. Secondly, vitamin D deficiency can be caused by a reduced food intake or, more specifically, a reduction in into previtamin D under the influence of ultraviolet light and then isomerizes to vitamin D. 8 Vitamin D and tuberculosis Vitamin D has been widely used to treat TB in the preantibiotic era. Already in 1848, a study was conducted about the role of cod liver oil, which is rich in vitamin D, and sun exposure as a treatment for TB. 44 In 1998, the first modern trial was conducted in children with TB, reporting that clinical improvement was faster in children taking vitamin D in addition to rifampicin, isoniazid, and streptomycin (TABLE 1) . 45 Later, Nursyam et al 46 confirmed the beneficial effect of the addition of vitamin D to standard TB medication in terms of the faster sputum conversion compared with the placebo group. The SUCCINCT study 47 showed that high -dose vitamin D supplementation on top of anti -TB drugs resulted in a faster radiographic improvement and weight gain in patients with TB. However, the study did not demonstrate a difference in sputum smear conversion rates or TB scores. In addition, low baseline vitamin D levels were found to significantly impact the response to treatment, suggesting that vitamin D can boost host immunity dependent on the initial serum levels. 47 Recently, an Egyptian group also reported that vitamin D supplementation resulted in a faster sputum smear conversion and TB score.
48
In contrast to the studies showing the beneficial effect of vitamin D supplementation, several studies could not support these findings.
20,49,50
Wejse et al 49 did not observe a positive effect of vitamin D on TB score, weight gain, sputum fatty fish consumption. Particularly in patients suffering from severe respiratory illness, financial means and energy to sustain a healthy diet are often missing. CF can be associated with pancreatic insufficiency, which affects absorption of fat -soluble vitamins A, D, E, and K and may lead to severe deficiency despite oral supplementation. 8 In addition, an increased catabolism or a decreased vitamin D synthesis due to aging or inflammatory processes can reduce 25(OH)D synthesis in the skin. 33,34 In many lung diseases, patients are treated with steroids, which may further impair vitamin D status through catabolic pathways. 35 Finally, polymorphisms in vitamin D -related genes may affect 25(OH)D levels. For example, in COPD, 2 variants in vitamin D -binding protein, rs7041 (TT carriers) and rs4588 (AA carriers), were associated with significantly lower 25(OH)D levels. 6 Although vitamin D deficiency is highly prevalent in lung diseases, the question remains whether it is a consequence rather than a direct cause of the disease. One way to explore this question is to see whether vitamin D deficiency enhances the risk for an incident disease in a prospective follow -up design. For instance, a significant association between low 25(OH)D levels and a more rapid decline in lung function has been documented in several prospective cohort studies.
36-38 In addition, Afzal et al 37 linked lower 25(OH)D levels with the risk for developing COPD. In asthma, Camargo et al 39 found a significant inverse correlation between maternal vitamin D intake and wheezing in children at 3 years of age.
Another approach to investigate causality is through genetic studies. Genetic polymorphisms in key enzymes of the vitamin D pathway have been associated with an increased risk for asthma, COPD, and TB.
6,40 In particular, polymorphisms in the VDR gene are proven risk factors for asthma. 41 A recent meta -analysis also showed that homozygosity for the FokI polymorphism of the VDR gene is associated with an increased risk for TB. 40 Homozygosity for the T allele of the rs7041 variant in the vitamin D -binding protein gene increased the risk of COPD.
6 A final proof for causality is to be expected from intervention studies. As vitamin D deficiency cannot be imposed by interventions, reversing the negative effects of vitamin D deficiency by supplementation is a potent alternative. These studies will be discussed in the following paragraph. Currently, there is no clear evidence that vitamin D has a beneficial effect on the resolution of pneumonia. Perhaps the ongoing Lung VITAL study, which explores the effect of vitamin D and/ or marine omega -3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia risk, and lung function (ClinicalTrials.gov identifier, NCT01 728 571), will provide the final answer.
Vitamin D and chronic obstructive pulmonary disease We conducted a single -center randomized placebo -controlled study in 182 patients with moderate to severe COPD and a history of exacerbations. 58 Patients were supplemented with 100 000 IU of vitamin D or placebo every 4 weeks for 1 year (TABLE 3) . Despite the significant increase in 25(OH)D levels by vitamin D supplementation (20-52 ng/ml), no significant difference was found in the median time to the first or second exacerbation, annual exacerbation rate, survival, Chronic Respiratory Disease Questionnaire score, dyspnea, forced expiratory volume in 1 second (FEV 1 ), or fatigue between the group receiving vitamin D supplementation and the placebo group. A subanalysis in patients with severe vitamin D deficiency (<10 ng/ml) at baseline revealed a significant decrease in the rate of exacerbations per patient -year (risk ratio, 0.57; confidence interval [CI], 0.33-0.98; P = 0.042). In addition, the phagocytic capacity of monocytes was conversion, or mortality. In a study by Martineau et al, 20 vitamin D did not improve time to sputum conversion in the whole study population. However, sputum conversion was significantly faster in patients with the tt genotype of the TaqI polymorphism of the VDR gene. In contrast to the study of Martineau et al, 20 Tukvadze et al 50 could not confirm that the tt allele resulted in a faster sputum culture conversion for patients on vitamin D treatment, but the study was significantly underpowered. An alternative explanation for the negative results in the studies of Martineau et al 20 and Wejse et al 49 may be the low dosage of the intervention. 47 A meta -analysis of 5 trials 20, [45] [46] [47] 49 confirmed that despite a significant increase in 25(OH)D levels, there was no beneficial effect of vitamin D as a treatment for TB. 51 Overall, with a large heterogeneity of endpoints (sputum conversion, weight gain, clinical improvement) and dosing regimens, it is currently hard to determine whether vitamin D supplementation is beneficial as an add -on therapy for TB. As the current combination anti -TB treatment is very effective in non-drug -resistant TB, a clinical beneficial effect of vitamin D supplementation may be hard to achieve. Vitamin D and pneumonia Several studies have investigated the effect of vitamin D supplementation on acute pneumonia in children (TABLE 2) , [52] [53] [54] [55] which is still an important reason for childhood mortality. 56 None of these studies showed a beneficial effect of vitamin D on top of antibiotic treatment on the resolution of pneumonia.
52-54 One study demonstrated that children receiving vitamin D as an add -on therapy had a reduced risk of a second pneumonia episode in the next 90 days.
52
Gupta et al 55 reported a higher relative likelihood of pneumonia resolution in the group receiving vitamin D supplementation, but there was no difference in the number of hospitalization days, Three studies also investigated the effect of vitamin D supplementation on physical performance in patients with COPD. In a post -hoc analysis of Lehouck et al, 58 Hornikx et al 63 studied the effect of monthly vitamin D supplementation in a 3 -month rehabilitation program in patients with COPD. Vitamin D supplementation resulted in a significant increase in maximal inspiratory strength and maximal oxygen uptake; a trend for an increased quadriceps strength and maximal expiratory strength without reaching significance was also revealed. In fact, these data suggested that vitamin D supplementation in respiratory diseases may also target other outcomes than the classic respiratory outcomes. Bjerk et al 64 conducted a pilot study in which participants received a daily dose of vitamin D (2000 IU) or placebo for 6 weeks. Although there was a significant increase in serum 25(OH)D levels, no improvements were found in the Short Physical Performance Battery or St George's Respiratory Questionnaire scores. 64 Another pilot study of Rafiq et al 65 did not show a positive effect on physical performance in 50 patients with COPD. However, a larger randomized placebo -controlled trial over a longer period is needed to draw a well--supported conclusion.
Currently, evidence suggests that vitamin D -deficient patients benefit from vitamin D supplementation to reduce the rate of exacerbations. The study of Rafiq et al 62 and a subsequent meta--analysis will finally address the issue of whether vitamin D supplementation in deficient patients with COPD should be recommended in a clinical setting to reduce exacerbations and improve physical functioning. increased in the supplemented group compared with placebo, particularly in the group with severe vitamin D deficiency. 58 Martineau et al 59 designed the multicenter ViDiCO trial to explore the role of vitamin D supplementation in a larger set of patients with COPD. They predefined a subanalysis in the vitamin D -deficient group and included more patients with COPD stages 1 to 3 according to the GOLD classification, as compared with the study of Lehouck et al. 58 A total of 240 patients were randomized to receive oral doses of 120 000 IU of vitamin D or placebo every 2 months for 1 year. Similarly to the study of Lehouck et al, 58 vitamin D supplementation had no effect on the time to the first upper respiratory infection or the median time to a moderate or severe exacerbation, although patients with severe vitamin D deficiency [serum 25(OH)D levels <50 nmol/l] had a reduced risk of moderate to severe exacerbation. In addition, supplementation with vitamin D significantly decreased symptoms of exacerbations, as illustrated by a decrease in the mean peak symptom score and a lower exacerbation score after the exacerbation. 59 Around the same time, Zendedel et al 60 showed a decrease in the number of COPD exacerbations and a significant improvement in FEV 1 in patients with severe and very severe COPD receiving vitamin D supplementation. Whether this effect was stronger in vitamin D -deficient patients is unknown because 25(OH)D levels were not measured.
More recently, Sanjari et al 61 were interested in the effect of cholecalciferol (vitamin D 3 ) or calcitriol [1,25(OH)2D] on pulmonary function, as compared with placebo. Patients with COPD with an exacerbation were treated for 7 days, but no effect of vitamin D supplementation was found either on FEV 1 or forced vital capacity (FVC). As patients were only treated and followed for 7 days, the impact of the intervention on future exacerbations or hospitalizations could not be evaluated.
Another multicenter double -blind placebo--controlled intervention study is currently recruiting participants (ClinicalTrials.gov identifier, NCT02 122 627). In this study, Rafiq et al 62 will also reported a significant reduction in the levels of tumor necrosis factor α at week 12.
73 In addition, Simoneau et al 70 investigated the effect of vitamin D supplementation on body mass index, FEV 1 , and the levels of immunoglobulins G and E and C -reactive protein, but could not demonstrate any effect of the intervention, presumably due to the short duration of the study.
A recent study compared the efficacy of vitamin D 2 and D 3 supplementation in raising 25(OH)D levels as well as its effect on respiratory health in patients with CF. High -dose supplementation was needed to raise 25(OH)D levels. In addition, when combining the groups receiving vitamin D 2 and D 3 supplementation, the plasma interleukin -8 concentration decreased. Supplementation with vitamin D 3 also improved FVC, and a positive correlation was detected between 25(OH)D levels and the quality of life, as measured by the Cystic Fibrosis Questionnaire-Revised, as well as changes in FEV 1 and FVC. 72 Therefore, large RCTs in patients with CF are needed to see how high -dose supplementation may normalize 25(OH)D levels to those associated with better respiratory health. Vitamin D and cystic fibrosis Most studies regarding vitamin D supplementation in patients with CF have focused on increasing 25(OH)D levels, calcium balance, and bone health. These studies show that even despite supplementation, it remains hard to raise 25(OH)D levels in this population, [66] [67] [68] and that a higher dosage regimen is needed to increase 25(OH)D levels (TABLE 4). [69] [70] [71] [72] Two studies, one conducted in adults 69 and the other in children, 70 compared the effects of ergocalciferol (vitamin D 2 ) and cholecalciferol (vitamin D 3 ) on 25(OH)D levels. Both treatments resulted in a significant increase in 25(OH)D levels to overall sufficient levels in the study of Khazai et al, 69 while vitamin D levels exceeding 30 ng/ml were only reached in 66% of patients in the study of Simoneau et al. 70 While no preference for either vitamin D 2 or D 3 treatment was found in the study of Simoneau et al, 70 a preference for vitamin D 3 was found in the study of Khazai et al.
69
A few studies also looked at the effect of vitamin D on pulmonary function or markers of inflammation in CF. In the study of Grossman et al, 71 patients with CF hospitalized for an exacerbation received a single dose of 250 000 IU, which increased the number of hospital -free days to over 6 months. In addition, a positive trend of supplementation was found for lung function recovery, 1 -year survival, and a decreased number of home intravenous antibiotic therapy days. They Several trials also investigated whether vitamin D supplementation during pregnancy could decrease asthma in the offspring. 92, 93 However, in these 2 RCTs, vitamin D supplementation had no beneficial effect on wheezing, although both studies may have been underpowered.
92-94
Overall, the collected evidence points to a positive effect of vitamin D on the risk reduction of severe exacerbations, regardless of the baseline levels. An effect of vitamin D supplementation for pregnant women to reduce wheezing of their offspring could not be demonstrated. (TABLE 5) . The meta -analysis could not show a beneficial effect of vitamin D supplementation on the prevention of asthma exacerbation, fractional exhaled nitric oxide levels, FEV 1 %, or asthma symptoms. 74 A more recent meta -analysis of RCTs on the use of vitamin D supplementation in asthma 82 included 9 clinical studies, 7 of which were conducted in 435 children 76,77,83-87 and 2 in 658 adults.
79,80
All studies with a follow -up of less than 12 weeks, those with no outcome other than bone health, or studies that were not placebo controlled were excluded, which led to the exclusion of 3 studies used in the meta -analysis of Luo et al.
75,78,81
Although all studies in this meta -analysis used supplementation with cholecalciferol, there was a high heterogeneity in the used dosages (500-1200 IU/d) and dosing regimens (once daily to every 2 months). Vitamin D supplementation significantly reduced the rate of asthma exacerbations treated with systemic corticosteroids (odds ratio [OR], 0.63; 95% CI, 0.45-0.88) 79, 80, 82, 87 and tended to increase the time to first exacerbation (P = 0.052). 79, 80, 82 In addition, vitamin D significantly reduced the risk of patients having at least 1 emergency visit or hospitalization for an exacerbation (OR, 0.39; 95% CI, 0.19-0.78).
77, 79, 80, 82, 84, 87 These effects are mainly attributable to studies performed in adults. Therefore, generalization of these results to children should be done with caution. 82 The meta -analysis could not identify a beneficial effect of vitamin D supplementation on FEV 1 or asthma control test scores. 82 Of note, 2 recent intervention studies demonstrated a positive effect on asthma control and lung function.
88,89
The beneficial effect of vitamin D supplementation on asthma exacerbations was recently shown the vitamin D -deficient subgroup. Moreover, intervention studies so far have been very heterogeneous in terms of the dose, dose regimen, and route of administration. Based on a large meta--analysis of individual patient data, one may say
The most important factor to explain the negative findings in vivo is the nonappropriate design of the clinical trial. Most studies are conducted in a relatively small sample size, in a heterogeneous population, and with no focus on that a daily dose in the vitamin D -deficient subgroup is probably the most efficient therapeutic approach. Several lung diseases clearly benefit from vitamin D supplementation. In adult asthma and vitamin D -deficient patients with COPD, the evidence is compelling and may be transferred to clinical recommendations or guidelines, while in other disease groups such as CF, pneumonia, and TB more and larger studies are warranted. Future studies should determine if vitamin D administration through inhalation may exert a more potent direct effect.
